LUNDBECK-FOUNDATION
5.3.2024 16:31:25 CET | Business Wire | Press release
The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience. This year’s award recognizes the pioneering work of three leading neuroscientists – Professor Larry Abbott at Columbia University (USA), Professor Terrence Sejnowski at the Salk Institute (USA), and Professor Haim Sompolinsky at Harvard University (USA) and the Hebrew University (Israel).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305504553/en/
Credit: The Lundbeck Foundation
Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance. The winners of The Brain Prize 2024 have made pioneering contributions to these scientific areas by uncovering some of the principles that govern the brain’s structure, function, and the emergence of cognition and behaviour.
The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.
Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:
“It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience. The three scientists have applied novel and sophisticated approaches from physics, mathematics, and statistics to study the brain. They have developed vital tools for the analysis of highly complex datasets acquired by modern day experimental neuroscientists.
The three prize winners have also proposed conceptual frameworks for understanding some of the brain’s most fundamental processes such as learning, memory, perception and how the brain generates maps of the external world. They have also provided crucial new insights into what may go awry in several devastating disorders of the nervous system, such as epilepsy, Alzheimer’s disease, and schizophrenia. In addition, their scientific achievements have paved the way for the development of brain-inspired artificial intelligence, one of the emerging and transformational technologies of our time.”
On behalf of the Lundbeck Foundation, CEO Lene Skole extends her warmest congratulations to each of the three Brain Prize recipients:
“Their pioneering research has created trailblazing knowledge and paved the way for other scientists to better understand critical brain functions, also in relation to diseases. It aligns fully with our purpose of bringing discoveries to lives. Each of their scientific endeavours began in the 70’s, and their determination, courage and persistence over decades should serve as inspiration for other scientists, and indeed be rewarded.”
FACTS
The human brain consists of approximately 100 billion neurons connected by trillions of synaptic connections. Every function the brain performs relies on the flow of information through these staggeringly complex networks of neurons. A fundamental goal of neuroscience is to understand how these networks are wired together, and how the patterns of neural activity within them give rise to cognition and behaviour. The sheer complexity of the brain means that understanding its language requires theoretical and computational approaches.
Theoretical and computational neuroscience uses mathematics, computer science, theoretical analysis, and abstractions of the brain to understand the principles that govern its structure, how it processes information, generates behaviour, and gives rise to cognitive abilities as perception, imagination, intelligence, the formation of knowledge, memory, problem-solving, decision-making, and the production of language. The field has laid the foundations for the development of AI - one of the most revolutionary developments in modern science.
MORE INFO
Find out more – see the information pack of The Brain Prize 2024 >>
About The Brain Prize
The Brain Prize is the world’s largest neuroscience research prize, and it is awarded each year by the Lundbeck Foundation. The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research. Recipients of The Brain Prize may be of any nationality and work in any country in the world. Since it was first awarded in 2011, The Brain Prize has been awarded to 47 scientists from 10 ten different countries. The Brain Prize recipients are presented with their award by His Royal Highness, King Frederik of Denmark, at a ceremony in the Danish capital, Copenhagen.
About the Lundbeck Foundation
The Lundbeck Foundation is an enterprise foundation encompassing a comprehensive range of commercial and philanthropic activities – all united by its strong purpose; Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner of several international healthcare and medtech companies – Lundbeck, Falck, ALK, Ellab, and Ferrosan Medical Devices – and an active investor in business, science and people through its commercial investments in the financial markets; in biotech companies based on Danish research and through philanthropic grants to science talents and programmes in Danish universities. The Foundation’s philanthropic grants amount to more than DKK 500m annually primarily focusing on the brain – including the world’s largest personal prize awarded in neuroscience, The Brain Prize.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305504553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release
Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release
- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC
SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 14:06:00 CEST | Press release
Integrated execution model combines multiple disciplines to improve recovery from mature offshore assets Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase reco
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 12:00:00 CEST | Press release
Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
